Jr. Michael Conick Hanley - 11 Feb 2026 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Reporting relationship: CHIEF OPERATING OFFICER
Issuer ticker: ANRO
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 17:17:31 UTC
Prior SEC filing: 08 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Erin R. McQuade, Attorney-in-Fact

Key filing fact

Jr. Michael Conick Hanley filed Form 4 for Alto Neuroscience, Inc. (ANRO) on 13 Feb 2026.

Key facts

This page summarizes Jr. Michael Conick Hanley's Form 4 filing for Alto Neuroscience, Inc. (ANRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 17:17.

Change

Previous filing in this sequence was filed on 08 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001791413 Primary reporting owner

Hanley Jr. Michael Conick

Relationship: CHIEF OPERATING OFFICER
Address: C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUTAIN VIEW
Signature: /s/ Erin R. McQuade, Attorney-in-Fact
Signature date: 13 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANRO transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +131,000
Change %
Price: $0.000000
Shares after: 131,000
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 131,000
Exercise price: $16.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.